Mr. Tang is an international partner based in the Beijing and Shanghai offices. Mr. Tang has extensive experience in the areas of M&A, corporate finance, foreign direct investments, private equity and venture capital, capital markets and general corporate matters. He particularly focuses on cross-border transactions involving both private and public companies.

Mr. Tang is licensed to practice law in both China and the State of New York.

Mr. Tang joined Haiwen in 2016. Prior to joining Haiwen, Mr. Tang practiced more than eight years with Davis Polk & Wardwell LLP and O'Melveny & Myers LLP.

Mergers & Acquisitions 

● Advised institutional clients on their equity or asset acquisitions, including Warburg Pincus on its acquisition of Leyou and ZSM Healthcare, Alibaba on its acquisition of a number of high-tech targets, Brilliance on its acquisition of the China operations of Bristol Myers Squibb, investment funds on their acquisition of the control stake of Genor Biopharma, Cultural Investment Holdings on its acquisition of Framestore, Chinese consortium on its acquisition of Playtika from Caesars Entertainment, clients on their proposed acquisition of Philips’ LED/auto lighting business and the China operations of Metro AG, and Changyou’s acquisition of the 17173 business from Sohu

● Advised on corporate sales, including a leading online game operator on its sale to CMC, a Chinese medical device manufacturer on its sale to SSI, the sale of automobile insurance business by a Chinese SaaS operator to RELX, GEDU on its strategic sale to Pearson Group, and CAGR Gas on its sale of urban gas assets

● Represented clients in complex mergers, carve-outs, restructuring and other transactions, including the business reorganization and change of control transaction involving Bitmain, Pfizer’s exit of its stake in the joint venture company Hisun Pfizer and related business collaborations, certain institutional clients on their participation in the merger of Ele.me and Baidu’s food delivery business

● Advised on going-private transactions involving ANE Global Logistics, Ruhnn, Sinovac Biotech (Kexing), Kongzhong.net, ShangPharma, Feihe Dairy, iKang Healthcare, 7 Days Inn, etc.

Private Equity and Venture Capital

● Representation of private equity and other clients, such as Sequoia, Warburg Pincus, TPG, Hillhouse Capital, Bain Capital, Alibaba, Ant Group, Hopu, China Life Investment, IDG, SAIF Partners, CDH, Banyan Capital and Asia Green Fund, in a wide range of their investment transactions, including offshore- and onshore-structured investments, strategic and financial investments, investments in growth- or early-stage companies, equity or equity-linked debt investments, etc.

● Assisted numerous clients at different life stages with their financing and other transactions

● Mr. Tang has aadvised on the private equity and venture capital transactions involving Pony.AI, Yuanqi Senlin, Grab Taxi, SheIn, Didi, Pinduoduo, Cambricon Tech, LightAI, Ant Group, Narwal Robotic, AIPark, Zai Lab, Mobvoi, ZLonGame, I-Mab Biopharma, Innovent Biologics, Amcare, We Doctor, Jenscare Scientific, LePure Biotech, Miotech, iFlyTech Health, ZTO Express, Kidswant, Ele.me, Dingdong, Full Truck, SF Express, AMEC Inc., Miniso, Douyu, UCWEB, Uber China, LinkedIn China, eHi, Hive Box, etc.  

Foreign Direct Investment

● Represented a number of international clients including Siemens, FMI, Hexion, Mirion, CLSA, J.P. Morgan, Caterpillar, Aetna, GEFCO, Ankura, Uber, Nova Credit and Scientific Games on their foreign direct investments in China

● Advised on a wide range of joint venture and business collaboration transactions, including the joint venture transaction between GE and Harbin Electric, Postal Savings Bank of China on its business alliance with, and sale of $7 billion worth of equity stake to strategic financial institutions, Pony.AI on its joint venture transaction with Sinotrans, CVS on its proposed joint venture transactions with Chinese leading pharmaceutical companies, the joint venture transaction between Foxconn and a Chinese private equity fund, etc.

Capital Markets

● Initial public offering and follow-on offerings by Xizhi Tech, Pony.ai, Mobvoi, DSC, Cloudbreak, Lotus Car, Genor Biopharma, Jenscare, DADA, eHang, JD.com, 58.com, Legend Holdings, China Mobile Game, Tarena, Zhongpin and Global Education & Technology Group in the U.S. and Hong Kong 

General Corporate Practice

Regularly advise on general corporate matters for companies in diverse industries, including TMT, biotech, healthcare, retail and consumer products, AI, fintech, mobility, semiconductors, etc.

LL.M., Columbia Law School (2010)

LL.B., Tsinghua University (2005)

Ranked by Chambers Greater China for Private Equity & Venture Capital and Corporate/M&A, 2024–2026

Recognized by The Legal 500 as a Leading Individual for M&A and recommended for Private Equity and Capital Markets, 2024–2026

Highly Regarded for Private Equity by IFLR1000, 2022–2025

Named an ALB Top 15 Rising Star (2022) and recognized in ALB Asia Deal Lawyers – China (2025)